Deruxtecan

Deruxtecan is a chemical compound and a derivative of exatecan that acts as topoisomerase I inhibitor.

It is available linked to specific monoclonal antibody (antibody–drug conjugate), such as:

• Trastuzumab deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma.
• Patritumab deruxtecan, an experimental antibody–drug conjugate to treat non-small-cell lung cancer.
• Ifinatamab deruxtecan, an experimental anti-cancer treatment.
• Datopotamab deruxtecan (Datroway), used for the treatment of breast cancer

References